Related references
Note: Only part of the references are listed.CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
Y-T Tai et al.
LEUKEMIA (2014)
Zoom Zoom: Racing CARs for Multiple Myeloma
Marcela V. Maus et al.
CLINICAL CANCER RESEARCH (2013)
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter et al.
CLINICAL CANCER RESEARCH (2013)
Evaluation of TNF superfamily molecules in multiple myeloma patients: Correlation with biological and clinical features
Dorota Lemancewicz et al.
LEUKEMIA RESEARCH (2013)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo et al.
BLOOD (2012)
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Eric Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
Andrzej J. Jakubowiak et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Despite quintuple disappointments, Lilly still charms investors
Kathleen Raven
NATURE MEDICINE (2012)
'Big data' deal for diabetes clinical trial modelling DEAL WATCH
Charlotte Harrison
NATURE REVIEWS DRUG DISCOVERY (2012)
APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status
John Quinn et al.
BLOOD (2011)
Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans
Tsunehiro Mizushima et al.
GENES TO CELLS (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Antibody-Based Therapies in Multiple Myeloma
Yu-Tzu Tai et al.
BONE MARROW RESEARCH (2011)
Antibody-drug conjugates: targeted drug delivery for cancer
Stephen C. Alley et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Milatuzumab - a promising new immunotherapeutic agent
Zuzana Berkova et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Therapeutic antibodies for autoimmunity and inflammation
Andrew C. Chan et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood
Shigeru Iida et al.
BMC CANCER (2009)
Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
Dharminder Chauhan et al.
CANCER CELL (2009)
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
Hiroshi Ikeda et al.
CLINICAL CANCER RESEARCH (2009)
The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
Stephen C. Alley et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Antibody-maytansinoid conjugates for the treatment of myeloma
Robert J. Lutz et al.
MABS (2009)
Contribution of linker stability to the activities of anticancer immunoconjugates
Stephen C. Alley et al.
BIOCONJUGATE CHEMISTRY (2008)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu
Yu-Tzu Tai et al.
BLOOD (2008)
APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells
Elodie Belnoue et al.
BLOOD (2008)
Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker
Ezogelin Oflazoglu et al.
CLINICAL CANCER RESEARCH (2008)
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
Eric D. Hsi et al.
CLINICAL CANCER RESEARCH (2008)
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
Charlotte F. McDonagh et al.
MOLECULAR CANCER THERAPEUTICS (2008)
IRF4 addiction in multiple myeloma
Arthur L. Shaffer et al.
NATURE (2008)
Antibody targeting of B-cell maturation antigen on malignant plasma cells
Maureen C. Ryan et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL
April Chiu et al.
BLOOD (2007)
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment
Yu-Tzu Tai et al.
CANCER RESEARCH (2006)
Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin g on antibody-dependent cellular cytotoxicity through its high binding to FcγRIIIa
S Iida et al.
CLINICAL CANCER RESEARCH (2006)
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
J Moreaux et al.
BLOOD (2005)
Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys
P Sapra et al.
CLINICAL CANCER RESEARCH (2005)
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor
R Bellucci et al.
BLOOD (2005)
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
J Moreaux et al.
BLOOD (2004)
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
AJ Novak et al.
BLOOD (2004)
BCMA is essential for the survival of long-lived bone marrow plasma cells
BP O'Connor et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells
P Tassone et al.
BLOOD (2004)
BAFF selectively enhances the survival of plasmablasts generated from human memory B cells
DT Avery et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
A molecular compendium of genes expressed in multiple myeloma
JO Claudio et al.
BLOOD (2002)
Dendritic cells, BAFF, and APRIL: Innate players in adaptive antibody responses
ICM MacLennan et al.
IMMUNITY (2002)
Share Paper
